Mr. Thomas Smeenk reports

HEMOSTEMIX LAUNCHES ENHANCED HUBSPOT-POWERED WEBSITES TO SUPPORT GLOBAL MARKETING & SALES OF ACP-01 FOR NO-OPTION PATIENTS

Hemostemix Inc. has launched a newly upgraded corporate website, fully integrated by HubSpot, representing a significant improvement in regulatory compliant marketing and sales functionalities.

Under physician order, following informed consent, Florida's law SB 1768 permits the use of VesCell in patients with life-threatening or debilitating conditions who have exhausted standard-of-care treatment options.

Website comparison: then versus now:

• Current version (today built on HubSpot): As compared with static information, the new websites harnesses HubSpot infrastructure and artificial-intelligence-powered functionalities to deliver best-in-class marketing, sales and engagement efficiencies. Key enhancements include:
  • Automated administrative workflows: HubSpot-integrated AI agents and Hemostemix salesman will manage scheduling, billing and follow-ups projected to reduce operational overhead.
  • Artificial-intelligence-driven patient and clinician engagement: Patient portals will include HIPAA-compliant patient engagement, including AI agent support, patient treatment by clinic and trial recruitment matching tools designed to enhance the user experience.

How marketing and sales teams will leverage the new platform

This upgraded digital framework positions Hemostemix to significantly accelerate ACP-01 adoption in Florida and other jurisdictions offering compassionate access:

1. Streamlined lead generation and nurturing: HubSpot's CRM and inbound marketing tools provide dashboards for tracking physician outreach, patient inquiries and clinic on-boarding.
2. Efficient patient intake and scheduling: Artificial-intelligence-powered scheduling and automated follow-up workflows allow rapid response to no-option patient referrals, significantly increasing hands-on patient interactions.
3. Targeted clinical partner outreach in Florida: Focused content campaigns will be deployed by medical speciality, for example, vascular surgeons and cardiologists, enabling the recent expansion of the marketing team dedicated to Florida operations to build expertise by disease type and treatment specialist.
4. Seamless trial matching and on-boarding: AI agents filter patient eligibility by patient self-identification, facilitate match to treatment protocols and assist with logistics across jurisdictions.
5. Operational monitoring and scalability: Real-time analytics -- powered by HubSpot's dashboards -- track campaign performance, patient engagement metrics and sales funnels, allowing management to scale deployment to matched with manufacturing capacity.

Strategic impact:

• Enhanced cost-efficiency: Administrative savings of up to 20 per cent translate into more resource allocation for business development.
• Improved patient access: Faster intake, artificial-intelligence-powered support and multilingual chatbot capabilities increase reach to no-option patients in their language of choice in regulatory-permissive environments.
• Sales growth: Integrated workflows support deployment into geographic markets to fuel marketing and sales efforts of ACP-01.

Forward outlook

The upgraded websites are a strategic cornerstone in Hemostemix's commercialization road map, supporting rapid patient intake response, while enabling stronger governance and compliance. As regulatory opportunities evolve jurisdiction by jurisdiction, this digital foundation ensures Hemostemix is well positioned to scale to serve vulnerable patient populations globally, compliantly.

Summary for shareholders:

• Website evolution: the Hemostemix and the Vescell Health websites were shifted from a static info-only presence to an interactive, HubSpot-enabled marketing and CRM sales platform;
• Capabilities gained: automation, AI engagement, optimized workflows and analytics;
• Business leverage: supports Florida-focused physician and patient outreach, compassionate-use sales, and scalable global expansion;
• Operational and financial benefits: tools for the company's multilingual marketing campaigns and global sales growth within a one-write sales funnel that populates management's dashboard.

"This amplifies the impact of recent financings," stated Thomas Smeenk, chief executive officer. "In this one step, we moved from a static website to an integrated marketing and sales platform that dashboards activities and the sales funnel results in real time," Mr. Smeenk said.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research and Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years as a midpoint result.

We seek Safe Harbor.